MWNA
NBIX icon

Marshall Wace North America’s Neurocrine Biosciences NBIX Stock Holding History

Marshall Wace North America’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-6,896
Closed -$663K – 1479
2020
Q3 		$663K Buy
+6,896
New +$798K ﹤0.01% 904
2020
Q2 		– Sell
-2,149
Closed -$186K – 1357
2020
Q1 		$186K Buy
2,149
+573
+36% +$56.1K ﹤0.01% 905
2019
Q4 		$169K Sell
1,576
-134,365
-99% -$14.1M ﹤0.01% 1000
2019
Q3 		$12.3M Buy
+135,941
New +$12.7M 0.07% 231
2019
Q2 		– Sell
-580,904
Closed -$51.2M – 1446
2019
Q1 		$51.2M Buy
580,904
+264,402
+84% +$22.1M 0.36% 82
2018
Q4 		$22.6M Sell
316,502
-158,938
-33% -$15.2M 0.22% 97
2018
Q3 		$58.5M Sell
475,440
-127,535
-21% -$14.5M 0.4% 63
2018
Q2 		$59.2M Buy
602,975
+164,189
+37% +$14.7M 0.33% 68
2018
Q1 		$36.4M Sell
438,786
-115,402
-21% -$9.75M 0.18% 132
2017
Q4 		$43M Sell
554,188
-160,280
-22% -$10.9M 0.24% 95
2017
Q3 		$43.6M Buy
714,468
+152,128
+27% +$8.03M 0.28% 85
2017
Q2 		$25.9M Sell
562,340
-249,540
-31% -$12.1M 0.19% 139
2017
Q1 		$34.9M Buy
+811,880
New +$34.8M 0.28% 104

Other funds holding NBIX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Marshall Wace North America's NBIX Position: Q4 2020 in Review

Marshall Wace North America sold out of Neurocrine Biosciences (NBIX) in Q4 2020, closing a stake of 6,896 shares — an estimated $663K sold.

Marshall Wace North America first reported a position in NBIX in Q1 2017 and held it in 13 quarters. The position peaked at $59.2M in Q2 2018. 406 funds tracked by Wall St. Rank hold NBIX as of Q4 2020.

  • Marshall Wace North America reported no remaining Neurocrine Biosciences position as of Q4 2020 after selling out during the quarter.
  • Marshall Wace North America sold 6,896 Neurocrine Biosciences shares in Q4 2020, an estimated $663K.
  • Marshall Wace North America first reported a position in Neurocrine Biosciences in Q1 2017 and held it in 13 quarters.
  • Marshall Wace North America's Neurocrine Biosciences position peaked at $59.2M in Q2 2018.
  • 406 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2020.

Based on Marshall Wace North America's 13F filing for Q4 2020, filed 16 Feb 2021.